ALMS
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-Mediated Diseases
时间：2025-02-07 05:15:00 市场： 美股 综合
Late-Breaking Data at Eadv of Esk-001, an Oral Tyk2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses With Sustained Increases Over 28 Weeks in Phase 2 Ole Study
时间：2024-09-27 21:00:01 市场： 综合 美股